A unique resource providing researchers from Texas A&M and the Texas Medical Center with access to state-of-the-art tools to support the discovery of new drugs and new treatments for some of the most devastating diseases of our time. The Combinatorial Drug Discovery Program resides in the Texas A&M Health Science Center's Institute of Biosciences and Technology. This core provides industry standard high throughput screening and microscopy capabilities to scientists carrying out chemical and genomic biochemical and drug discovery research. The core supports investigators from all of the institutions in and around the Houston/Galveston region and with pharmaceutical and biotechnology partners. The core provides many benefits, such as access to an automated infrastructure that is capable of supporting both biochemical and cell-based screens. The core also provides ready access to a collection of nearly 60,000 drugs, investigational agents and small molecules. Our collections of test agents include current FDA-approved clinical candidates and off-patent drugs exhibiting the ‘drug-like’ qualities of acceptable solubility, desirable ADME/toxicology properties and adequate bioavailability. These properties are important for rapid advancement of new agents into successful preclinical and clinical trials by discovering new therapeutic vulnerabilities alone or in combinations. We also have collections of mechanistically annotated informer sets that are pathway specific modulators for studying mechanism of action. The core also has collections of natural products and diverse sets of small molecules that can be interrogated for new target discovery. The greatest benefit of the core; however, is its fulltime professional staff. The screening team is composed of highly experienced biologists, biochemists, pharmacologists and bio-informaticians with pharmaceutical industry and academic experience. Each project is individually evaluated and a team of scientists from the core is created to fit the specific needs of the project from assay development through primary, secondary and orthogonal screening. The team is committed to providing an integrated and highly collaborative program with every investigator.
Clifford Stephan, PhD
Research Associate Professor
Center for Translational Cancer Research